"Dr. Suhy, a pioneer of the RNAi industry, was already developing therapeutic candidates in this field in 2003 before the concept of RNAi was accepted in the scientific community," said
Regen's Chief Scientific Officer, Dr.
A spokesperson for the Company provided further insight on RNAi, stating this is a process by which genes may be selectively blocked using a natural mechanism the body normally uses to protect against viruses. The Nobel Prize in Medicine was awarded to Fire and Mello in 2006 for making this discovery.
Regen Chief Scientific Officer Dr.
"With Regen's background in the field of tumor immunology, their licensed intellectual property from Benitec Biopharma, and clinical expertise, I look forward to assisting the Company in developing their protocols with the end goal being taking this safe and nontoxic cancer therapy to patients," said Dr. Suhy.
1. Zheng et al. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer. 2013 Feb 15;132(4):967-77.
2. Zheng et al. Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference. J Immunol. 2006 Oct 15;177(8):5639-46.
About Regen BioPharma:
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Bio-Matrix Scientific Group, Inc.and Regen BioPharma Inc. David R. Koos, PhD Chairman & Chief Executive Officer 619-702-1404 www.regenbiopharma.com